Actively Recruiting

Age: 40Years +
All Genders
NCT07270172

The MICRON Study - A Steno 1 Substudy

Led by University of Aarhus · Updated on 2026-02-02

40

Participants Needed

5

Research Sites

161 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this observational study is to compare cardiac and renal oxygen consumption among subjects with type 1 diabetes treated with either multifactorial intervention or according to the current standard care. Participants are recruited from a main study /the Steno1 study) responsible for the intervention. The main questions it aims to answer are if a multifactorial intervention in subjects with type 1 diabetes targeting cardiovascular and renal risk factors, will reduce cardiac and renal oxygen demand. Participants will undergo the following examinations at 0-month, 6-month, and 24-month after enrolling in the main study: * Measurement of cardiac and real oxygen consumption (\[11C\]acetate PET/CT-scan) * Measurement of kidney function (\[99mTc\]DTPA GFR measurement) * Measurement of markers of heart and kidney disease in blood and urine samples.

CONDITIONS

Official Title

The MICRON Study - A Steno 1 Substudy

Who Can Participate

Age: 40Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female persons 40 years old or older with type 1 diabetes diagnosed before age 30 with insulin from onset, or if diagnosed after 30 years, insulin from onset with diabetic ketoacidosis or positive autoantibodies
  • Duration of diabetes over 10 years
  • Presence of chronic kidney disease (urine albumin-creatinine ratio >30 mg/g or estimated glomerular filtration rate <60 ml/min/1.73 m2) OR history of ischemic heart disease (myocardial infarction, stroke, or angina) OR history of heart failure OR obesity grade 2 or 3 (BMI >35 kg/m2) OR 5-year cardiovascular disease risk >10% according to Steno Type 1 Risk Engine
  • Fertile females must use highly effective contraception methods during the study and for at least 2 months after stopping study drug, or be in menopause, surgically sterilized, or hysterectomized for at least 12 months prior to screening
  • Ability to communicate with the investigator and understand informed consent
  • Given written informed consent
Not Eligible

You will not qualify if you...

  • Type 2 diabetes, maturity-onset diabetes of the young, or secondary diabetes
  • History of pancreatitis
  • Body mass index less than 18.5 kg/m2
  • Females of childbearing potential who are pregnant, breastfeeding, intend to become pregnant, or are not using adequate contraception
  • Known or suspected abuse of alcohol or recreational drugs
  • Participation in another drug intervention study
  • Chronic kidney disease stage 5
  • Active malignant disease
  • Use of study drugs (SGLT inhibitors, GLP-1 receptor agonists, or finerenone) at inclusion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Aarhus University Hospital

Aarhus N, Denmark, 8200

Actively Recruiting

2

Regionshospitalet Gødstrup

Gødstrup, Denmark, 7400

Actively Recruiting

3

Regionshospitalet Horsens

Horsens, Denmark, 8700

Actively Recruiting

4

Regionshospitalet Silkeborg

Silkeborg, Denmark, 8600

Actively Recruiting

5

Regionshospitalet Vibrg

Viborg, Denmark, 8800

Actively Recruiting

Loading map...

Research Team

S

Sofie H Wilken, MD, PhD student

CONTACT

J

Jakob A Østergaard, MD, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here